Patents by Inventor Pasi Janne

Pasi Janne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220106310
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 7, 2022
    Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
  • Publication number: 20220090203
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 24, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • Publication number: 20220017510
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 20, 2022
    Inventors: NATHANAEL S. GRAY, JAEBONG JANG, DRIES DE CLERCQ, MICHAEL ECK, PASI JANNE
  • Patent number: 11186574
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 30, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
  • Publication number: 20210355119
    Abstract: The application relates to a compound having Formula I which modulates the activity of HER2 and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof plays a role.
    Type: Application
    Filed: June 14, 2019
    Publication date: November 18, 2021
    Inventors: NATHANAEL S. GRAY, JAEBONG JANG, PASI JANNE, JIEUN SON
  • Publication number: 20210340102
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: June 15, 2021
    Publication date: November 4, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John Hatcher, Nathanael S. Gray, Hwangeun Choi, Pasi Janne, Tinghu Zhang
  • Patent number: 11161842
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jaebong Jang, Dries De Clercq, Michael Eck, Pasi Janne
  • Patent number: 11066363
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: July 20, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John Hatcher, Nathanael S. Gray, Hwangeun Choi, Pasi Janne, Tinghu Zhang
  • Publication number: 20210207223
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Application
    Filed: November 12, 2020
    Publication date: July 8, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Patent number: 11009508
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 18, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, Board of Regents of the University of Texas System
    Inventors: Kwok-Kin Wong, Bruce E. Johnson, Pasi A. Janne, Hongbin Ji, Nabeel Bardeesy, Norman E. Sharpless, Diego H. Castrillon
  • Publication number: 20210094913
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 1, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • Publication number: 20210085688
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 25, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK
  • Publication number: 20210077469
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 18, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20210078977
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Inventors: Nathanael S. GRAY, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG
  • Publication number: 20210040088
    Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 11, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Patent number: 10870636
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 22, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Pasi Janne, Hwan Geun Choi, Jaebong Jang
  • Publication number: 20200390783
    Abstract: The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 17, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Patent number: 10865451
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • Publication number: 20200377501
    Abstract: The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER